Abstract
Carcinoma of the breast in male gender is rare, presents less than 1% of all breast cancers. Risk factors include these following characteristics: family history, genetic abnormalities,conditions associated with relative hyper estrogenism, prior chest wall irradiation and some drugs.Most patients present with a painless, firm, subareolar lump, may be associated by clinical gynecomastia and nipple retraction, a bloody nipple discharge, skin ulceration and Paget's disease. The most common types of invasive carcinoma are infiltrating ductal adeno carcinoma and papillary carcinoma. Diagnostic tools are meticulous history and clinical examination. Mammography may be helpful. Magnetic resonance imaging in male breast cancer might has same benefits and restrictions as in female breast cancer. Surgery remains the most important and effective treatment modality for breast cancer in men. Sentinel lymph node biopsy seems to be a simple and reliable method for staging the axilla accurately, avoiding unnecessary radical treatment of uninvaded lymph nodes. The role of adjuvant therapy in male breast cancer is less well established than those in female cancer and has not been evaluated in randomized clinical trials. Hormonal therapy is recommended in all receptor-positive patients. There is a clear indication for radiotherapy when it is impossible to lift the entire tumour burden from the axilla.
Keywords:
Male, breast, cancer
References
1
Wainwright JN. Carcinoma of the male breast: Clinical and pathologic study. Arch Surg,1927;14:836-59.
2
Buzdar AU. Breast cancer in Men. Oncology (Williston Park), 2003;17(10):1661-64,
3
Joseph A, Mokbel K. Male breast cancer. Int J Fertil Womens Med. 2004;49(5):198-99
4
Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(1):20-6.
5
Volm MD. Male breast cancer. Curr Treat Options Oncol 2003;4(2):159-64.
6
Tischkowitz MD, Hodgson SV, Fentiman IS. Male breast cancer: aetiology, genetics and clinical management. Int J Clin Pract, 2002;56(10):750-54
7
O\'Malley C, Shema S, White E. Incidence of male cancer in California 1988-2000: racial/ethnic variation in 1759 men. Breast Cancer Res Treat, 2005;93(2):145-50.
8
Giordano SH. A review of diagnosis and management of male breast cancer. Oncologist, 2005;10(7):471-9.
9
Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Int Med, 2002;137(8):678-87.
10
Blaumeiser B, Tjalma WAA, Verslegers I, De Schepper AM, Buytaert P. Invasive papillary carcinoma of the male breast. Eur Radiol, 2002;12:220710.
11
Meguerditchian AN, Falardeau BA, Martin G. Male breast carcinoma. J Can Chir, 2002;45(4):296-302.
12
Gennari R, Curigliano G, Jereczek-Fossa BA et al. Male breast cancer: a special therapeutic problem. Anything new? (Review). Int J Oncol, 2004 ;24(3):663-70.
13
Coard K, McCartney T. Bilateral synchronous carcinoma of the male breast in a patient receiving estrogen therapy for carcinoma of the prostate: cause or coincidence? South Med J, 2004;97(3):308-10.
14
Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer following breast cancer in men. J Natl Can Inst, 2002;94(17):1330-32.
15
Wilson CH, Griffith CD, Shrimankar J, Douglas F. Gynaecomastia, neurofibromatosis and breast cancer. Breast, 2004;13(1):77-9.
16
Thorlacius S, Tryggvadottir L, Olafsdottir GH et al. Linkage To BRCA2 region in hereditary male breast cancer. Lancet. 1995;346:544-45.
17
Brenner B, Fried G, Levitzki P et al. Male breast carcinoma in Israel: higher incident but possibly prognosis in Ashkenazi Jews. Cancer, 2002;15;94(8):2128-33.
18
Gerber B, Mylonas I. Reduction of the risk of breast cancer. Zentralbl Gynakol, 2003;125(1):6-16
19
D\'avanzo B, La Vecchia C. Risk factors for male breast cancer. Br J Cancer, 1995;71:1359-62.
20
Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L. et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet,. 1998;352:1337-39.
21
Eeles RA, Powles TJ. Chemoprevention options for BRCA1 and BRCA2 mutation carriers. J Clin Oncol, 2000;18(21):93-99.
22
Peto J, Collins N, Barfoot R. et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early onset breast cancer. J Natl Cancer Inst, 1999;91:943-49.
23
Pharoah PD, Lipscombe JM, Redman KL, et al. Familial predisposition to breast cancer in a British population: Implications for prevention. Eur J Cancer, 2000;36:773-79.
24
Brewster A, Helzlsouer K. Breast cancer epidemiology, prevention, and early detection. Curr Opin Oncol., 2001;13(6):420-25.
25
Hadjisavvas A, Charalambous E, Adamou A et al. BRCA2 germline mutations in Cypriot patients with familial breast/ovarian cancer. Hum Mutat, 2003;21(2):171.
26
Ford D, Easton DF, Bishop DT. et al. Risks of cancer in BRCA1-mutation carriers. Lancet, 1994;343:692-95.
27
Phelan CM, Lancester JM, Tonin P. et al. Mutation analysis of the BRCA2 gene in 49 sitespecific breast cancer families. Nat Genet, 1996;13:20-122.
28
Arver B, Du Q, Chen J et al. Hereditary breast cancer: A review. Cancer Biol, 2000;10:271-88
29
Tonin PN. Genes implicated in hereditary breast cancer syndromes. Sem Surg Oncol, 2000;18:281-86.
30
Ottini L, Masala G, D\'Amico C et al. BRCA1 and BRCA2 mutation status and tumour characteristics in male breast cancer: a population-based study in Italy. Cancer Res, 2003;15;63(2):342-47.
31
Ribiero G, Swindell R, Harris M et al. A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. The Breast, 1996;5:141-45.
32
Gross PE, Reid C, Pintilie M et al. Male breast carcinoma: a review of 229 patients who presented to the princess Margaret Hospital during 40 years:1955-1996. Cancer, 1999;85:6629-39.
33
Dicker AP. The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by anti androgen mono therapy. Lancet Oncol, 2003;4:30-6.
34
Muir D, Kanthan R, Kanthan SC. Male versus female breast cancers. Apopulation-based comparative immuno histochemical analysis. Arch Pathol. Lab Med, 2003;127(1):36-41.
35
Wang-Rodriguez J, Cross K, Gallagher S et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol, 2002;15(8):853-61.
36
De Bree E, Askoxylakis J, Giannikaki E et al. Secretory carcinoma of the male breast. Ann Surg Oncol, 2002;9(7):663-67.
37
Simmons RM. Male ductal carcinoma in situ presenting as bloody nipple discharge: A case report and literature review. The Breast, 2002;8(1):112-14
38
Hittmair AP, Lininger RA, Tavassoli FA. Ductal carcinoma in situ (DCIS) in the male breast. Cancer, 1998;85:2139-49.
39
Anderson WF, Althuis MD, Brinton LA et al. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat, 2004 ;83(1):77-86.
40
Olsson H. Estrogen receptor content in malignant breast tumors in men--a review.J Mammary Gland Biol Neoplasia, 2000;5(3):283-7.
41
Volpe C, Raffetto JD, Collure DW et al. Unilateral male breast masses: Cancer risk and their final evaluation and management. Am J Surg, 1999;65:250-53.
42
Joshi A, Kapila K, Verma K. Fine needle aspiration cytology in the management of male breast masses. Nineteen years of experience. Acta Cytol, 1999;43:334-38.
43
Kapila K, Verma K. Cytology of nipple discharge in florid gynecomastia. Acta Cytol, 2003;47(1):36-40
44
Westenend PJ, Jobse C. Evaluation of fine-needle aspiration cytology of breast masses in males. Cancer, 2002;25;96(2):101-4.
45
Gennari R, Renne G, Travaini L et al. Sentinel node biopsy in male breast cancer: future standard treatment. Eur J Surg, 2000;167:461-62.
46
Gennari R, Ballardini B, Costa A. Biopsy of axillary and internal mammary sentinel node for complete nodal staging in male breast cancer. Eur J Surg Oncol, 2000;28:557-59.
47
Veronesi U, Marubini E, Mariani L et al. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. Thirty-year results of a randomized trial. Eur J Cancer, 1999;35:1320-25.
48
Cimmino VM, Degnim AC, Sabel MS et al. Efficacy of sentinel lymph node biopsy in male breast cancer.J Surg Oncol, 2004;1;86(2):74-7.
49
Gennari R, Scelsi M, Greco B et al. Complete nodal staging in male breast cancer. (Biopsy of axillary and internal mammary sentinel node. J Exp Clin Cancer Res, 2004;23(1):163-5.
50
De Cicco C, Baio SM, Veronesi P et al. Sentinel node biopsy in male breast cancer. Nucl Med Commun, 2004 ;25(2):139-43.
51
Vetto J, Paddoch D, Eppich H et al. Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg, 1999;177:379-83.
52
Gough DB, Donohue JH, Evans MM et al. A 50-year experience of male breast cancer: Is outcome changing? Surg Oncol, 1993;2:325-33.
53
Albo D, Ames FC, Hunt KK et al. Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy. Breast Cancer Res Treat, 2003;77(1):9-14.
54
Tischkowitz MD, Hodgson SV, Fentiman IS. Male breast cancer: aetiology, genetics and clinical management Int J Clin Pract, 2002;56(10):750-54
55
Chakravarthy A, Kim CR. Post-mastectomy radiation in male breast cancer. Radiother Oncol, 2002;65(2):99-103 .
56
Patel HZ 2nd, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast. Cancer, 1989;64:158-85.
57
Giordano SH, Valero V, Buzdar AU et al. Efficacy of Anastrozole in male breast cancer. Am J Clin Oncol, 2002;25(3):235-37.
58
Zabolonty BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol, 2005;1;90(1):26-30.
59
Donegan WI, Redlich PN, Lang PJ et al. Carcinoma of the breast in males: A multi institutional survey. Cancer, 1998;83:498-509.
60
Wick MR, Sayadi H, Ritter JH. Low stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma. Am J Clin Pathol, 1999;111:59-69.
61
Lopez M, Di Lauro L, Lazzaro B et al. Hormonal treatment of disseminated male breast cancer. Oncology, 1985;42:345-49.
